Market Cap 605.70M
Revenue (ttm) 0.00
Net Income (ttm) -161.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 863,500
Avg Vol 974,426
Day's Range N/A - N/A
Shares Out 46.38M
Stochastic %K 77%
Beta N/A
Analysts Strong Sell
Price Target $27.15

Company Profile

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's diseas...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 984 6300
Address:
800 Chesapeake Drive, Redwood City, United States
NoRiskNoFun
NoRiskNoFun Sep. 3 at 7:48 PM
$ALMS $MLTX $MPLT huge sell off $RARE
0 · Reply
NoRiskNoFun
NoRiskNoFun Sep. 1 at 7:18 PM
$ALMS $MPLT $XBI price is 1/3 if it fair value because of semifailed trial of secobd line drug🤡🤡🤡🤡
0 · Reply
MarkIIIGold
MarkIIIGold Sep. 1 at 7:11 PM
$MPLT $45。
0 · Reply
MarkIIIGold
MarkIIIGold Sep. 1 at 5:48 PM
$MPLT Bullish
0 · Reply
NoRiskNoFun
NoRiskNoFun Sep. 1 at 3:59 PM
0 · Reply
LivermoresGhost
LivermoresGhost Aug. 26 at 4:23 AM
$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $VENU $CAAS $MPLT $RDIB
0 · Reply
BioRich
BioRich Aug. 25 at 7:02 PM
$OTLK $RGNX $MPLT $CAPR. Nice to see 4 of my Top 5 winners being what I called distressed (or disconnect) stocks. Damaged, but not done. The other in the Top 5, $ABCL, is not distressed. In fact, it's a foundational portfolio lock. $OTLK - Most challenged. Approval, relative silence, awaiting direction. Good entry point, but low expectations. Fits more into the flipper zone right now rather than a conviction play. $RGNX - Recent market overreaction caused this to drop ~25%. That freed up cheap shares. Overall pipeline and cash in tact, RGNX-201 has the potential to be a catalyst pop if/when clinical hold removed. $MPLT - Another massive overreaction where the thesis remained intact. Had been lulling us to sleep, but it's starting to wake up a bit. Worth a watch or strong starter position. $CAPR - The holy grail here. Recent developments position them to what I believe is a favorable FDA decision later this year. SP is massively depressed and could be a blind buy until $11.
0 · Reply
Quantumup
Quantumup Aug. 24 at 11:32 AM
H.C. Wainwright⬆️ $LBRX's PT to $60,⬆️PoA, reiterated Buy and said -- LB Pharmaceuticals' lead asset, LB-102, is a novel benzamide in late-stage clinical development for psychosis and mood disorders. $BMY $MPLT ABBV PRAX TEVA NMRA VNDA SNY XENE BHVN RAPP Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2091851044753940939?s=20
0 · Reply
PaulMacfarland845
PaulMacfarland845 Aug. 22 at 3:43 PM
$XERS $MPLT $BOT $IPO $HHIS.TSX Xeris advances drug-delivery and specialty therapies, MPLT remains speculative, BOT remains speculative, IPO remains tied to new-listing activity, and HHIS.TSX remains speculative. I'm watching clinical milestones, funding, IPO sentiment, and liquidity.
0 · Reply
prismmarketview
prismmarketview Aug. 14 at 1:37 PM
$150 million is going behind the next stage of schizophrenia drug development. MapLight Therapeutics ($MPLT) raised $150M following positive Phase 2 results for ML-007C-MA, including a signal in cognition. Across the field, companies are targeting different gaps in schizophrenia care: longer-acting treatments at $TEVA, a newly approved option from $VNDA, and negative symptoms at $NERV. The pipeline is moving beyond controlling psychosis toward addressing more of the disease’s full burden. https:// prismmarketview.com/maplight-raise s-150-million-as-schizophrenia-drug-development-broadens/ $MPLT $TEVA $VNDA $NERV
1 · Reply
Latest News on MPLT
MapLight Therapeutics announces $150M private placement

2026-08-17T07:34:44.000Z - 18 days ago

MapLight Therapeutics announces $150M private placement


MapLight Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 22 days ago

MapLight Therapeutics Quarterly report: Q2 2026


MapLight Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 22 days ago

MapLight Therapeutics Earnings release: Q2 2026


MapLight Therapeutics downgraded to Neutral from Buy at UBS

2026-08-10T13:25:25.000Z - 25 days ago

MapLight Therapeutics downgraded to Neutral from Buy at UBS


MapLight Therapeutics downgraded to Neutral from Buy at UBS

2026-08-10T10:31:05.000Z - 25 days ago

MapLight Therapeutics downgraded to Neutral from Buy at UBS


MapLight Therapeutics Transcript: Study result

Jul 27, 2026, 8:00 AM EDT - 5 weeks ago

MapLight Therapeutics Transcript: Study result


MapLight Therapeutics Slides: Study result

Jul 27, 2026, 8:00 AM EDT - 5 weeks ago

MapLight Therapeutics Slides: Study result


MapLight Therapeutics Press release: Study result

Jul 27, 2026, 8:00 AM EDT - 5 weeks ago

MapLight Therapeutics Press release: Study result


MapLight Therapeutics Announces Changes to Board of Directors

Jun 24, 2026, 7:00 AM EDT - 2 months ago

MapLight Therapeutics Announces Changes to Board of Directors

CNS


MapLight Therapeutics Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MapLight Therapeutics Transcript: Study result


MapLight Therapeutics Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MapLight Therapeutics Press release: Study result


MapLight Therapeutics Slides: Study result

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MapLight Therapeutics Slides: Study result


MapLight Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

MapLight Therapeutics Earnings release: Q1 2026


MapLight Therapeutics Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

MapLight Therapeutics Quarterly report: Q1 2026


MapLight Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

MapLight Therapeutics Proxy statement: Proxy filing


MapLight Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

MapLight Therapeutics Proxy statement: Proxy filing


MapLight Therapeutics Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Annual report: Q4 2025


MapLight Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Earnings release: Q4 2025


MapLight Therapeutics Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Slides: Corporate presentation


MapLight Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 6:00 PM EDT - 5 months ago

MapLight Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


MapLight Therapeutics Slides: Corporate Presentation

Jan 9, 2026, 7:00 AM EST - 7 months ago

MapLight Therapeutics Slides: Corporate Presentation


MapLight Therapeutics Quarterly report: Q3 2025

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Quarterly report: Q3 2025


MapLight Therapeutics Earnings release: Q3 2025

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Earnings release: Q3 2025


MapLight Therapeutics Slides: Corporate Presentation

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Slides: Corporate Presentation


MapLight Therapeutics Announces Pricing of Initial Public Offering

Oct 26, 2025, 5:30 PM EDT - 10 months ago

MapLight Therapeutics Announces Pricing of Initial Public Offering


MapLight Therapeutics IPO Registration Document (S-1)

Sep 19, 2025, 4:11 PM EDT - 11 months ago

MapLight Therapeutics IPO Registration Document (S-1)


MapLight Therapeutics Registration statement: Registration Filing

Sep 19, 2025, 7:00 AM EDT - 11 months ago

MapLight Therapeutics Registration statement: Registration Filing


NoRiskNoFun
NoRiskNoFun Sep. 3 at 7:48 PM
$ALMS $MLTX $MPLT huge sell off $RARE
0 · Reply
NoRiskNoFun
NoRiskNoFun Sep. 1 at 7:18 PM
$ALMS $MPLT $XBI price is 1/3 if it fair value because of semifailed trial of secobd line drug🤡🤡🤡🤡
0 · Reply
MarkIIIGold
MarkIIIGold Sep. 1 at 7:11 PM
$MPLT $45。
0 · Reply
MarkIIIGold
MarkIIIGold Sep. 1 at 5:48 PM
$MPLT Bullish
0 · Reply
NoRiskNoFun
NoRiskNoFun Sep. 1 at 3:59 PM
0 · Reply
LivermoresGhost
LivermoresGhost Aug. 26 at 4:23 AM
$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $VENU $CAAS $MPLT $RDIB
0 · Reply
BioRich
BioRich Aug. 25 at 7:02 PM
$OTLK $RGNX $MPLT $CAPR. Nice to see 4 of my Top 5 winners being what I called distressed (or disconnect) stocks. Damaged, but not done. The other in the Top 5, $ABCL, is not distressed. In fact, it's a foundational portfolio lock. $OTLK - Most challenged. Approval, relative silence, awaiting direction. Good entry point, but low expectations. Fits more into the flipper zone right now rather than a conviction play. $RGNX - Recent market overreaction caused this to drop ~25%. That freed up cheap shares. Overall pipeline and cash in tact, RGNX-201 has the potential to be a catalyst pop if/when clinical hold removed. $MPLT - Another massive overreaction where the thesis remained intact. Had been lulling us to sleep, but it's starting to wake up a bit. Worth a watch or strong starter position. $CAPR - The holy grail here. Recent developments position them to what I believe is a favorable FDA decision later this year. SP is massively depressed and could be a blind buy until $11.
0 · Reply
Quantumup
Quantumup Aug. 24 at 11:32 AM
H.C. Wainwright⬆️ $LBRX's PT to $60,⬆️PoA, reiterated Buy and said -- LB Pharmaceuticals' lead asset, LB-102, is a novel benzamide in late-stage clinical development for psychosis and mood disorders. $BMY $MPLT ABBV PRAX TEVA NMRA VNDA SNY XENE BHVN RAPP Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2091851044753940939?s=20
0 · Reply
PaulMacfarland845
PaulMacfarland845 Aug. 22 at 3:43 PM
$XERS $MPLT $BOT $IPO $HHIS.TSX Xeris advances drug-delivery and specialty therapies, MPLT remains speculative, BOT remains speculative, IPO remains tied to new-listing activity, and HHIS.TSX remains speculative. I'm watching clinical milestones, funding, IPO sentiment, and liquidity.
0 · Reply
prismmarketview
prismmarketview Aug. 14 at 1:37 PM
$150 million is going behind the next stage of schizophrenia drug development. MapLight Therapeutics ($MPLT) raised $150M following positive Phase 2 results for ML-007C-MA, including a signal in cognition. Across the field, companies are targeting different gaps in schizophrenia care: longer-acting treatments at $TEVA, a newly approved option from $VNDA, and negative symptoms at $NERV. The pipeline is moving beyond controlling psychosis toward addressing more of the disease’s full burden. https:// prismmarketview.com/maplight-raise s-150-million-as-schizophrenia-drug-development-broadens/ $MPLT $TEVA $VNDA $NERV
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 14 at 8:59 AM
$MPLT my summary assessment for anyone interested https://substack.com/profile/160232761-biotech-pharma-investor/note/c-314520519?r=2nece1
0 · Reply
QuantInsider
QuantInsider Aug. 13 at 8:58 PM
$MPLT is taking a hit, down nearly 13% in the last five sessions Today’s little bounce doesn’t change the bearish vibe The options tape is showing heavy buying of long-dated, deep ITM puts About $1M worth of Feb 2027 $30 puts swept at the ask Institutions seem to be hedging for more downside even with that $150M financing news Looks like they’re not betting on a big reversal anytime soon
0 · Reply
NoRiskNoFun
NoRiskNoFun Aug. 10 at 2:28 PM
$UWMC $HTZ $TENX $SION $MPLT play coin toss game!
0 · Reply
NoRiskNoFun
NoRiskNoFun Aug. 10 at 12:27 PM
$MPLT $CVRX $TENX $SION $KPTI strong rebound!
0 · Reply
SHVR89
SHVR89 Aug. 7 at 6:10 PM
$MPLT longterm
1 · Reply
hawkmdend
hawkmdend Aug. 3 at 2:06 PM
$MPLT PPS should be $8 or lower. Their next PR should be about their earnings release and business update.
1 · Reply
SHVR89
SHVR89 Aug. 3 at 1:18 AM
$MPLT I see an oportunity on this, last year bought $MLTX and $NTLA on a similar patern Look like swing or even position trade to me GLE Watch fillings tomorrow can be different
1 · Reply
MarkIIIGold
MarkIIIGold Aug. 1 at 4:12 PM
$MPLT buy much as you can. Short is very stupid at the level.
1 · Reply
hawkmdend
hawkmdend Aug. 1 at 2:19 AM
$MPLT No, two of their drugs failed(compared to the standard of care).
0 · Reply
WVU1
WVU1 Jul. 31 at 7:21 PM
$MPLT Great buying opportunity.
0 · Reply
LittleBagBob
LittleBagBob Jul. 31 at 2:10 PM
$MPLT @Pika_Capital what is your take? If you don’t mind.
1 · Reply
MesserschmittBavaria
MesserschmittBavaria Jul. 31 at 6:19 AM
$MPLT pay attention before other news I’ll wait for my investment
0 · Reply